Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abbisko Cayman Limited ( (HK:2256) ) has provided an announcement.
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has dosed the first patient in a Phase 1 clinical trial for ABSK131, a novel PRMT5*MTA inhibitor targeting advanced or metastatic solid tumors with MTAP deficiency. This development follows the investigational drug’s IND clearance by both the China National Medical Products Administration and the U.S. FDA. The trial aims to assess the safety and efficacy of ABSK131, which has shown promise in preclinical studies for selectively targeting MTAP-deleted cancer cells. This advancement could potentially position Abbisko Therapeutics as a significant player in the oncology sector, especially in developing targeted therapies for cancers with high MTAP deficiency rates, such as mesothelioma and pancreatic cancer.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Therapeutics Co., Ltd., founded in April 2016 and based in Shanghai, is an oncology-focused biopharmaceutical company dedicated to the discovery and development of innovative medicines for unmet medical needs in China and globally. The company has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.
Average Trading Volume: 4,304,993
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.48B
See more insights into 2256 stock on TipRanks’ Stock Analysis page.